Clinical trials: Lung Hypoplasia
Idiopathic Pulmonary Fibrosis
Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants
This is a phase I, First-in-Human study in healthy participants, performed at a single study center, consisting of 2 parts: Part 1 is a single ascending dose (SAD) study and Part 2 is a multiple ascending dose (MAD) study.
- Trial name
- NCT05134727
- Testing
- AZD5055
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Breast Cancer, Non-small Lung Cancer
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
This is an open-label, multicenter, dose-escalation study designed to assess the safety, tolerability, and pharmacokinetics of oral GDC-0032 administered in combination with either docetaxel or with paclitaxel.
- Trial name
- NCT01862081
- Testing
- Docetaxel, GDC-0032, Paclitaxel
- Where
- 14 sites in United States, Belgium and 2 more
- Volunteers
- 80 people
- Sponsor
- Genentech, Inc.
Non-small Cell Lung Cancer
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
The purpose of this study is to evaluate the safety and anti-tumor effect of rociletinib when administered in combination with trametinib.
- Trial name
- NCT02580708
- Testing
- Rociletinib, Trametinib
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Clovis Oncology, Inc.
Non-small Cell Lung Cancer Metastatic
T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer
This is a single site, non-randomized trial for the assessment of intravenous (IV) pembrolizumab (also known as MK-3475) combined with pemetrexed/platinum-based chemotherapy in subjects with advanced or metastatic non-squamous…
- Trial name
- NCT06045767
- Testing
- Pembrolizumab 50 MG Injection [Keytruda]
- Volunteers
- 30 people
- Sponsor
- Ari Raphael
Non-Small Cell Carcinoma of Lung
Aspects of Quality of Life During Adjuvant Oncological Treatment for Locally Advanced Lung Cancer Which Include Immune Checkpoint Inhibitor.
Current oncological treatment for patients with locally advanced lung cancer comprise adjuvant immunotherapy (immune checkpoint inhibitors-ICI) as an additional one-year treatment after chemoradiotherapy which increases overall…
- Trial name
- NCT07754409
- Where
- Sweden
- Volunteers
- 75 people
- Sponsor
- Göteborg University
Non Small-cell Lung Cancer
Liquid Biopsy for Early Non-small Lung Cancer Detection
This clinical trial will assess the performance of a liquid biopsy assay to identify cancer in indeterminant pulmonary nodules identified by CT screening of high-risk individuals and evaluate the capability of the liquid biopsy…
- Trial name
- NCT05462795
- Testing
- Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule, Liquid biopsy for aberrant DNA methylation analysis - Known lung cancer for surgical resection, Liquid biopsy for aberrant DNA methylation analysis - Healthy volunteer
- Where
- United States
- Volunteers
- 171 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia
Feto-Endoscopic Tracheal Occlusion (FETO) for Severe Congenital Diaphragmatic Hernia
Tracheal occlusion IDE approved by FDA for congenital diaphragmatic hernia fetuses.
- Conditions
- Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia, Pulmonary; Hypertension
- Trial name
- FETO (NCT02986087)
- Testing
- Fetal Tracheal Occlusion
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Lung Cancer
Endobronchial Ultrasound Versus Mediastinoscopy in Patients With Non-Small Cell Lung Cancer (NSCLC)
The goal of this clinical research study is to compare 2 different methods for checking lymph glands (in the middle of the chest) for cancer cells.
- Trial name
- NCT00559611
- Testing
- Endobronchial Ultrasound, Mediastinoscopy
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Non-Small-Cell Lung
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
This clinical trial is studying nonsquamous non-small cell lung cancer (NSCLC). Participants in this study must have cancer that has spread through their body or can't be removed with surgery.
- Trial name
- NCT06012435
- Testing
- sigvotatug vedotin, docetaxel
- Where
- 331 sites in United States, Argentina and 23 more
- Volunteers
- 762 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Lung Cancer, Breast Cancer
Observational Study Evaluate Pathology Practice Use Artificial Intelligence in Patient Suspected Lung and Breast Cancer
A multinational observational study to evaluate the current pathology practices and the utilization of computational pathology plus artificial intelligence algorithms in patients with suspected lung and breast cancer.
- Trial name
- CASCADE (NCT06827132)
- Where
- 2 sites in Brazil, Kenya
- Volunteers
- 603 people
- Sponsor
- AstraZeneca
Non-small-lung-cell Cancer, NSCLC
Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients
This study is a randomized, multicenter clinical study ，which is designed to compare the efficacy of the safety and efficacy of treatment every 6 weeks in EGFR positive (Non-small cell lung cancer, NSCLC) with concurrent Driver…
- Conditions
- Non-small-lung-cell Cancer, NSCLC, EGFR Gene Mutation
- Trial name
- NCT04552613
- Testing
- EGFR-TKI, EGFR-TKI combined with chemotherapy (pemetrexed plus carboplatin)
- Where
- China
- Volunteers
- 114 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Non-small-lung-cell Cancer, NSCLC, Pembrolizumab
A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC)
This study is a randomized, national multicenter clinical study ，which is designed to compare the efficacy of the safety and efficacy of treatment every 3 weeks or 6 weeks in (Non-small-cell-cell cancer, NSCLC) subjects without…
- Trial name
- NCT04393883
- Testing
- A) Standard maintenance programme group, pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;, B) Improvement maintenance programme group, pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Patients With Metastatic Tumours (Colorectal Cancer, Non-small Lung Cancer, Renal Cell Carcinoma or Sarcoma )
Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours
Although it is usually described as an immunosuppressive modality and not thought of as immunotherapy, there are new preclinical evidences suggesting that high-dose ionizing irradiation (IR) results in direct tumour cell death…
- Trial name
- SABR-PDL1 (NCT02992912)
- Testing
- Anti-PD-L1 antibody atezolizumab, SABR
- Where
- France
- Volunteers
- 138 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Non-Small Cell Lung Cancer Metastatic
Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr
Non Small Cell lung cancer (NSCLC) remains the first cause of death by cancer in the World. For the patients presenting a NSCLC stage IV, the median of survival is about 15 months today.
- Trial name
- DICIPLE (NCT03469960)
- Testing
- Ipilimumab, Nivolumab
- Where
- 47 sites in France
- Volunteers
- 265 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Cancer
A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects
The purpose of this study is to determine the recommended dose and regimen for the orally administered MEK inhibitor GSK1120212 dosed in combination with everolimus in subjects with solid tumors.
- Trial name
- Cancer (NCT00955773)
- Testing
- GSK1120212 plus everolimus
- Where
- 3 sites in United States, France
- Volunteers
- 64 people
- Sponsor
- GlaxoSmithKline
Infant, Newborn, Infant, Low Birth Weight
Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure
This multicenter trial tested whether inhaled nitric oxide would reduce death or the need for oxygen in preterm infants (less than 34 weeks gestational age) with severe lung disease.
- Conditions
- Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
- Trial name
- Preemie iNO (NCT00016523)
- Testing
- Inhaled nitric oxide
- Where
- 17 sites in United States
- Volunteers
- 420 people
- Sponsor
- NICHD Neonatal Research Network
Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia
Safety and Efficacy of FETO in CDH: A Phase III Trial
Congenital diaphragmatic hernia (CDH) is a birth defect characterized by the development of a hole in the diaphragm, the breathing muscle that separates the chest from the abdomen.
- Trial name
- CHOP FETO (NCT06884423)
- Testing
- FETO with GoldBAL2 Balloon and BALTACCIBDPE100 Catheter
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Holly L Hedrick, MD
Small Cell Lung Cancer
A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung Cancer
This study is a randomized, multi-center clinical trial. Patients are stratified according to performance status (ECOG 0, 1 vs 2) and institution. Patients are randomized to 1 of 2 treatment arms.
- Trial name
- NCT00349492
- Testing
- IP
- Where
- 14 sites in South Korea
- Volunteers
- 372 people
- Sponsor
- Clinical Research Center for Solid Tumor, Korea
Resectable Non-small Lung Cancer
Association Between Circulating Immune Cells and the Tumor Immune Contexture in Resectable Non-small Cell Lung Cancer
With the recent approval of Nivolumab for second-line treatment of stage IIIb/IV non-small cell lung cancer (NSCLC), immune checkpoint inhibitors are entering the standard of care for lung cancer.
- Trial name
- LYMPHOLUNG (NCT02551211)
- Testing
- blood drawn, surgical resection of cancer
- Where
- France
- Volunteers
- 22 people
- Sponsor
- University Hospital, Rouen
Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer
Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
This phase 2 trial will evaluate the safety and efficacy of combining immunotherapy with a PD-1 checkpoint inhibitor (Pembrolizumab), an anti-VEGF receptor (Ramucirumab), and a taxane chemotherapy (Docetaxel) in treating patients…
- Conditions
- Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- DoceRamPem (NCT04340882)
- Testing
- Docetaxel, Pembrolizumab, Ramucirumab
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Emory University